A Double Blind Randomized Controlled Study to assess Efficacy of Nutritional Therapy for Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis

Deptt of Gastroenterology0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

研究概览

暂无简介。

•Liver cirrhosis (Child B or Child C class)
•Age between 18-60 years
•History of recovery from episode of overt hepatic encephalopathy (West-Haven grade 1 and above) in last 12 months

•Evidence of overt hepatic encephalopathy at the time of enrollment
•History of taking lactulose, rifaximin, neomycin, metronidazole, L-Ornithine L-Aspartate or probiotics in past 7 days.
•Alcohol intake during past 6 weeks.
•Receiving secondary prophylaxis for Spontaneous Bacterial Peritonitis.
•Previous transjugular intrahepatic portosystemic shunts or shunt surgery.
•Significant comorbid illness such as heart, respiratory or kidney failure,and neurological disease such as Alzheimerâ??s disease, Parkinsonâ??s disease and non hepatic Metabolic Encephalopathies.
•Receiving psychoactive drugs, promotility and hypomotility drugs
•Hepatocellular carcinoma
•Electrolyte abnormality (Serum sodium <125meq/L or serum potassium <2.5meq/L)
•Intercurrent infection such as spontaneous bacterial peritonitis
•Patients of acute on chronic liver failure (ACLF).

发起方

Deptt of Gastroenterology